Prokidney Corp Stock Current Valuation
| PROK Stock | USD 1.85 0.03 1.60% |
Valuation analysis of ProKidney Corp helps investors to measure ProKidney Corp's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The value of Enterprise Value Over EBITDA is expected to slide to -0.38. The value of Enterprise Value Multiple is estimated to slide to -0.38. Fundamental drivers impacting ProKidney Corp's valuation include:
Price Book 91.3172 | Enterprise Value -163.6 M | Enterprise Value Ebitda 2.1287 |
Overvalued
Today
Please note that ProKidney Corp's price fluctuation is dangerous at this time. Calculation of the real value of ProKidney Corp is based on 3 months time horizon. Increasing ProKidney Corp's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ProKidney Corp's intrinsic value may or may not be the same as its current market price of 1.85, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.85 | Real 1.62 | Target 15.33 | Hype 1.85 | Naive 1.89 |
The intrinsic value of ProKidney Corp's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence ProKidney Corp's stock price.
Estimating the potential upside or downside of ProKidney Corp helps investors to forecast how ProKidney stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ProKidney Corp more accurately as focusing exclusively on ProKidney Corp's fundamentals will not take into account other important factors: ProKidney Corp Company Current Valuation Analysis
ProKidney Corp's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ProKidney Corp Current Valuation | (163.63 M) |
Most of ProKidney Corp's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProKidney Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ProKidney Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ProKidney Corp is extremely important. It helps to project a fair market value of ProKidney Stock properly, considering its historical fundamentals such as Current Valuation. Since ProKidney Corp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProKidney Corp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProKidney Corp's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ProKidney Corp has a Current Valuation of (163.63 Million). This is 101.14% lower than that of the Biotechnology sector and 103.52% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.98% higher than that of the company.
ProKidney Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProKidney Corp's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProKidney Corp could also be used in its relative valuation, which is a method of valuing ProKidney Corp by comparing valuation metrics of similar companies.ProKidney Corp is currently under evaluation in current valuation category among its peers.
ProKidney Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (163.63 M) | ||||
| Shares Outstanding | 127.97 M | ||||
| Shares Owned By Insiders | 27.43 % | ||||
| Shares Owned By Institutions | 43.58 % | ||||
| Number Of Shares Shorted | 10.7 M | ||||
| Price To Book | 91.32 X | ||||
| EBITDA | (147.67 M) | ||||
| Net Income | (135.45 M) | ||||
| Cash And Equivalents | 21.88 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 4.41 M | ||||
| Debt To Equity | 5.66 % | ||||
| Current Ratio | 0.74 X | ||||
| Book Value Per Share | (7.66) X | ||||
| Cash Flow From Operations | (90.07 M) | ||||
| Short Ratio | 25.42 X | ||||
| Earnings Per Share | (0.54) X | ||||
| Target Price | 4.67 | ||||
| Number Of Employees | 163 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 1.81 B | ||||
| Total Asset | 420.55 M | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 349.11 M | ||||
| Net Asset | 420.55 M |
About ProKidney Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProKidney Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProKidney Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProKidney Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out ProKidney Corp Piotroski F Score and ProKidney Corp Altman Z Score analysis. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.